Volume
Open
Day's Low
Day's High
52 Wk Low
52 Wk High
Bid
Ask
EPS
PE Ratio
Shares
Market Cap
Dividend
Ex-Div Date
Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
...
Health Technology » Biotechnology
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| AMGN | Amgen Inc. | 0.08% | 171.44 | 1.3% | $495.59m | |
| BIIB | Biogen Inc. | -1.21% | 232.19 | 1.3% | $474.53m | |
| CELG | Celgene Corporation | -0.28% | 96.09 | 1.3% | $455.94m | |
| GILD | Gilead Sciences, Inc. | 0.96% | 67.14 | 0.9% | $438.91m | |
| ILMN | Illumina, Inc. | -0.21% | 312.17 | 3.5% | $317.03m | |
| REGN | Regeneron Pharmaceuticals, Inc. | -1.77% | 314.42 | 2.6% | $293.32m | |
| A | Agilent Technologies, Inc. | -2.60% | 66.20 | 1.6% | $202.25m | |
| VRTX | Vertex Pharmaceuticals Incorporated | -0.53% | 171.46 | 1.9% | $180.22m | |
| EXAS | Exact Sciences Corporation | -2.20% | 92.82 | 25.3% | $160.06m | |
| ALXN | Alexion Pharmaceuticals, Inc. | -1.30% | 125.89 | 2.0% | $147.69m | |
| BMRN | BioMarin Pharmaceutical Inc. | -0.63% | 87.14 | 4.3% | $117.80m | |
| SRPT | Sarepta Therapeutics, Inc. | -1.68% | 119.58 | 14.7% | $110.26m | |
| INCY | Incyte Corporation | 0.42% | 79.35 | 2.5% | $106.16m | |
| IONS | Ionis Pharmaceuticals, Inc. | -1.66% | 67.43 | 8.2% | $97.11m | |
| ALNY | Alnylam Pharmaceuticals, Inc | -1.76% | 66.62 | 9.2% | $93.27m |
Company Profile
Illumina, Inc. engages in the development and manufacture of integrated systems for the analysis of genetic variation and function. It operates through the Core Illumina and Consolidated Variable Interest Entity segments (VIE). The Core Illumina segments serve customers in the research, clinical and applied markets, and enable the adoption of genomic solutions. The Consolidated VIE segment includes activities of GRAIL and Helix. The company was founded by David R. Walt, John R. Stuelpnagel, Anthony W. Czarnik, Lawrence A. Bock, and Mark S. Chee in April 1998 and is headquartered in San Diego, CA.